Cancers (Jun 2022)
A Novel 2-Metagene Signature to Identify High-Risk HNSCC Patients amongst Those Who Are Clinically at Intermediate Risk and Are Treated with PORT
- Shivaprasad Patil,
- Annett Linge,
- Hannah Hiepe,
- Marianne Grosser,
- Fabian Lohaus,
- Volker Gudziol,
- Max Kemper,
- Alexander Nowak,
- Dominik Haim,
- Inge Tinhofer,
- Volker Budach,
- Maja Guberina,
- Martin Stuschke,
- Panagiotis Balermpas,
- Jens von der Grün,
- Henning Schäfer,
- Anca-Ligia Grosu,
- Amir Abdollahi,
- Jürgen Debus,
- Ute Ganswindt,
- Claus Belka,
- Steffi Pigorsch,
- Stephanie E. Combs,
- Simon Boeke,
- Daniel Zips,
- Korinna Jöhrens,
- Gustavo B. Baretton,
- Michael Baumann,
- Mechthild Krause,
- Steffen Löck,
- on behalf of the DKTK-ROG
Affiliations
- Shivaprasad Patil
- German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany and German Cancer Consortium (DKTK), partner site Dresden, 01307 Dresden, Germany
- Annett Linge
- German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany and German Cancer Consortium (DKTK), partner site Dresden, 01307 Dresden, Germany
- Hannah Hiepe
- OncoRay—National Center for Radiation Research in Oncology, Faculty of Medicine and UniversityHospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden—Rossendorf, 01307 Dresden, Germany
- Marianne Grosser
- Institute of Pathology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, 01307 Dresden, Germany
- Fabian Lohaus
- German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany and German Cancer Consortium (DKTK), partner site Dresden, 01307 Dresden, Germany
- Volker Gudziol
- Department of Otorhinolaryngology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, 01307 Dresden, Germany
- Max Kemper
- National Center for Tumor Diseases (NCT), Partner Site Dresden, Germany: German Cancer Research Center (DKFZ), Heidelberg, Germany; Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, 01307 Dresden, Germany; Helmholtz Association/Helmholtz-Zentrum Dresden—Rossendorf (HZDR), 01307 Dresden, Germany
- Alexander Nowak
- National Center for Tumor Diseases (NCT), Partner Site Dresden, Germany: German Cancer Research Center (DKFZ), Heidelberg, Germany; Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, 01307 Dresden, Germany; Helmholtz Association/Helmholtz-Zentrum Dresden—Rossendorf (HZDR), 01307 Dresden, Germany
- Dominik Haim
- National Center for Tumor Diseases (NCT), Partner Site Dresden, Germany: German Cancer Research Center (DKFZ), Heidelberg, Germany; Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, 01307 Dresden, Germany; Helmholtz Association/Helmholtz-Zentrum Dresden—Rossendorf (HZDR), 01307 Dresden, Germany
- Inge Tinhofer
- German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany, and German Cancer Consortium (DKTK), partner site Berlin, 10117 Berlin, Germany
- Volker Budach
- German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany, and German Cancer Consortium (DKTK), partner site Berlin, 10117 Berlin, Germany
- Maja Guberina
- German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany, and German Cancer Consortium (DKTK), partner site Essen, 45147 Essen, Germany
- Martin Stuschke
- German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany, and German Cancer Consortium (DKTK), partner site Essen, 45147 Essen, Germany
- Panagiotis Balermpas
- German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany, and German Cancer Consortium (DKTK), partner site Frankfurt, 60590 Frankfurt, Germany
- Jens von der Grün
- German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany, and German Cancer Consortium (DKTK), partner site Frankfurt, 60590 Frankfurt, Germany
- Henning Schäfer
- German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany, and German Cancer Consortium (DKTK), partner site Freiburg, 79106 Freiburg, Germany
- Anca-Ligia Grosu
- German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany, and German Cancer Consortium (DKTK), partner site Freiburg, 79106 Freiburg, Germany
- Amir Abdollahi
- German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany, and German Cancer Consortium (DKTK), partner site Heidelberg, 69120 Heidelberg, Germany
- Jürgen Debus
- German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany, and German Cancer Consortium (DKTK), partner site Heidelberg, 69120 Heidelberg, Germany
- Ute Ganswindt
- German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany, and German Cancer Consortium (DKTK), partner site Munich, 80336 Munich, Germany
- Claus Belka
- German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany, and German Cancer Consortium (DKTK), partner site Munich, 80336 Munich, Germany
- Steffi Pigorsch
- German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany, and German Cancer Consortium (DKTK), partner site Munich, 80336 Munich, Germany
- Stephanie E. Combs
- German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany, and German Cancer Consortium (DKTK), partner site Munich, 80336 Munich, Germany
- Simon Boeke
- German Cancer Research Center (DKFZ), 60120 Heidelberg, Germany and German Cancer Consortium (DKTK), partner site Tübingen, 72076 Tübingen, Germany
- Daniel Zips
- German Cancer Research Center (DKFZ), 60120 Heidelberg, Germany and German Cancer Consortium (DKTK), partner site Tübingen, 72076 Tübingen, Germany
- Korinna Jöhrens
- German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany and German Cancer Consortium (DKTK), partner site Dresden, 01307 Dresden, Germany
- Gustavo B. Baretton
- German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany and German Cancer Consortium (DKTK), partner site Dresden, 01307 Dresden, Germany
- Michael Baumann
- OncoRay—National Center for Radiation Research in Oncology, Faculty of Medicine and UniversityHospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden—Rossendorf, 01307 Dresden, Germany
- Mechthild Krause
- German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany and German Cancer Consortium (DKTK), partner site Dresden, 01307 Dresden, Germany
- Steffen Löck
- German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany and German Cancer Consortium (DKTK), partner site Dresden, 01307 Dresden, Germany
- on behalf of the DKTK-ROG
- DOI
- https://doi.org/10.3390/cancers14123031
- Journal volume & issue
-
Vol. 14,
no. 12
p. 3031
Abstract
(1) Background: Patients with locally advanced head and neck squamous cell carcinoma (HNSCC) who are biologically at high risk for the development of loco–regional recurrences after postoperative radiotherapy (PORT) but at intermediate risk according to clinical risk factors may benefit from additional concurrent chemotherapy. In this matched-pair study, we aimed to identify a corresponding predictive gene signature. (2) Methods: Gene expression analysis was performed on a multicenter retrospective cohort of 221 patients that were treated with postoperative radiochemotherapy (PORT-C) and 283 patients who were treated with PORT alone. Propensity score analysis was used to identify matched patient pairs from both cohorts. From differential gene expression analysis and Cox regression, a predictive gene signature was identified. (3) Results: 108 matched patient pairs were selected. We identified a 2-metagene signature that stratified patients into risk groups in both cohorts. The comparison of the high-risk patients between the two types of treatment showed higher loco–regional control (LRC) after treatment with PORT-C (p p = 0.027), i.e., the 2-metagene signature was indicative for the type of treatment. (4) Conclusion: We have identified a novel gene signature that may be helpful to identify patients with high-risk HNSCC amongst those at intermediate clinical risk treated with PORT, who may benefit from additional concurrent chemotherapy.
Keywords
- head and neck squamous cell carcinoma
- gene signature
- postoperative radiotherapy
- postoperative radiochemotherapy
- propensity score matching